OS THERAPIES INCORPORATED Increase (Decrease) in Prepaid Expense
OS THERAPIES INCORPORATED (OSTX) reported Increase (Decrease) in Prepaid Expense of $274.63 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-14
- OS THERAPIES INCORPORATED increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was $337.71K.
- OS THERAPIES INCORPORATED increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was -$63.08K.
- OS THERAPIES INCORPORATED increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$340.13K.
- OS THERAPIES INCORPORATED increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$348.75K.
- OS THERAPIES INCORPORATED increase (decrease) in prepaid expense for fiscal 2025 was -$1.04M.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $337.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $274.63K 10-Q · filed 2026-08-14 | -$65.51K derived: sum of 3 quarters · filed 2026-08-14 | -$414.26K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$63.08K 10-Q · filed 2026-05-18 | -$403.21K derived: sum of 2 quarters · filed 2026-05-18 | -$751.96K derived: sum of 3 quarters · filed 2026-05-18 | |
| 2025-12-31 | -$340.13K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$688.88K derived: sum of 2 quarters · filed 2026-03-31 | -$1.04M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$348.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$697.50K 10-Q · filed 2025-11-14 | ||
| 2025-06-30 | -$348.75K 10-Q · filed 2026-08-14 | |||
| 2024-09-30 | $35.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |